Genomic Analysis to Identify a Predictive Biomarker for Immunotherapy

Recruiting now

Conditions studied: Lung Cancer

In brief

This study is designed to identify the predictive biomarker for immunotherapy using patient samples (tumor tissue, blood, fecal material) who treated with immune checkpoint inhibitor.

Key facts

Study ID

NCT03578185

Run by

Se-Hoon Lee

People needed

800

Starts

2018-04-11

Expected to finish

2025-12-31

Last updated by the study team

2024-12-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• aged above or equal to 18
• Histologically confirmed lung cancer patients
• Patient treated with immune checkpoint inhibitor
• Exculsion Criteria:
• NA

Where it is running

• Samsung Medical Center — Seoul, Gangnam-gu, South Korea (enrolling)
• Seoul National University Hospital — Seoul, Joungro-gu, South Korea (enrolling)
• Asan Medical Center — Seoul, Songpa-gu, South Korea

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.